Catalog No.
Product Name
Application
Product Information
Citations
-
iNOS Inhibitor
BYK 191023 is a selective inhibitor of inducible nitric-oxide synthase (iNOS) that functions as an L-arginine competitive antagonist, exhibiting an IC50 value of 86 nM for iNOS, while displaying significantly higher IC50 values of 17 µM and 162 µM for neuronal (nNOS) and endothelial (eNOS) nitric-oxide synthases, respectively. This compound is vital for studying the role of iNOS in various pathological conditions and demonstrates potential applications in inflammation research and related disease models. -
NO Production Inhibitor
9-Hydroxy-α-lapachone is a natural phenolic compound that serves as an effective nitric oxide (NO) production inhibitor. It demonstrates significant inhibitory activity, with an IC50 value of 4.64 µM, against LPS-induced NO production in RAW 264.7 macrophage cells. This compound is utilized in research applications focused on understanding inflammatory responses and nitric oxide signaling pathways. -
NO Synthase Inhibitor
1,3-PBIT dihydrobromide is a selective inhibitor of inducible nitric oxide synthase (iNOS), demonstrating a Ki value of 47 nM. In contrast, it shows reduced inhibition for endothelial (eNOS) and neuronal nitric oxide synthase (nNOS), with Ki values of 9 µM and 0.25 µM, respectively, for purified human enzymes. While it effectively inhibits iNOS in vitro, its cellular activity may be limited by membrane permeability, making it primarily useful for biochemical studies on nitric oxide pathways and their related regulatory mechanisms. -
Cancer Biomarker
8-Nitroguanine is a product of nitrative DNA damage resulting from reactive nitrogen species and serves as a potential biomarker for cancer progression. This compound is particularly relevant in the study of malignant fibrous histiocytoma, providing insights into tumor development and response to treatment. Its role in oxidative stress pathways makes it a valuable tool for researchers investigating mechanisms of DNA damage and repair in cancer biology. -
Analgesic Agent
Dipyrocetyl is an analgesic agent that exhibits anti-inflammatory properties. This compound is utilized in research applications focused on pain management and inflammation pathways, providing valuable insights into potential therapeutic interventions for various inflammatory disorders. Its mechanism of action makes it a significant candidate for studies aimed at understanding pain relief mechanisms. -
NO Production Inhibitor
Sinomenine N-oxide is a potent inhibitor of nitric oxide (NO) production, exhibiting an IC50 value of 23.04 μM. This compound demonstrates significant anti-angiogenic, anti-inflammatory, and anti-rheumatic properties, making it valuable for research in cardiovascular and inflammatory diseases. Its mechanisms may offer insights into therapeutic approaches for conditions characterized by excess NO production. -
NO Inhibitor
Diplacol is a geranylated flavanone that functions as a nitric oxide (NO) inhibitor. Isolated from Paulownia coreana UYEKI, Diplacol exhibits notable anti-inflammatory activity. It effectively reduces NO production in LPS-stimulated Raw264.7 macrophage cells, with an IC50 value of 4.53 μM, making it a valuable reagent for studies focusing on inflammation and related signaling pathways. -
NOS Inhibitor
L-NAPNA is a selective nitric oxide synthase (NOS) inhibitor, demonstrated to have an IC50 of 1.4 μM. It exhibits significant analgesic effects, as evidenced by its ability to reduce formalin-induced paw licking behavior in mice (ED50 of 57.2 mg/kg) and diminish acetic acid-induced abdominal writhing (ED50 of 25 mg/kg). This compound is valuable for exploring therapeutic approaches in research focused on central nervous system disorders. -
Guanidino Compound
α-Guanidinoglutaric acid is a guanidino compound that has been identified in cobalt-induced epileptogenic foci within the cerebral cortex of feline subjects. This compound is known to induce epileptic seizures in rodent models following intraventricular administration, making it a valuable tool for studying the mechanisms of epilepsy and related neurological disorders. Its application is particularly relevant in pharmacological studies aimed at elucidating seizure activity and potential therapeutic interventions. -
NO Synthase Inhibitor
Corydaldine is an alkaloid that acts as an inhibitor of nitric oxide synthase (NOS). It has been shown to effectively reduce nitric oxide production in BV2 microglial cells upon stimulation with lipopolysaccharide (LPS). This compound is relevant for research focusing on neuroinflammation and the roles of nitric oxide in various neurodegenerative diseases. -
iNOS Inhibitor
AR-C102222 is a spirocyclic fluoropiperidine quinazoline that selectively inhibits inducible nitric oxide synthase (iNOS). This compound demonstrates significant potential in mitigating neuropathic pain by reducing excessive nitric oxide production. Its specificity for iNOS makes it a valuable tool for researchers investigating the role of nitric oxide in pain pathology and related therapeutic interventions. -
Anti-inflammatory Agent
Anti-inflammatory Agent 65 is a Hederagonic acid derivative that exhibits significant anti-inflammatory activity. This compound effectively inhibits the release of nitric oxide (NO) and prevents the nuclear translocation of IRF3 and p65. By disrupting the STING/IRF3/NF-κB signaling pathway, Anti-inflammatory Agent 65 significantly reduces the inflammatory response, making it a valuable tool for studying inflammation-related conditions and potential therapeutic interventions. -
iNOS Inhibitor
FR260330 is a selective, orally active inhibitor of inducible nitric oxide synthase (iNOS), functioning by suppressing iNOS dimerization. This compound significantly reduces nitric oxide accumulation in rat splenocytes and human DLD-110 cells, with IC50 values of 27 nM and 10 nM, respectively. FR260330 has demonstrated efficacy in ameliorating lipopolysaccharide-induced inflammatory responses in rat models, making it a valuable tool for researchers investigating inflammatory diseases and related pathways. -
NO Production Inhibitor
Anhydronotoptol is a potent inhibitor of nitric oxide (NO) production. It effectively inhibits NO generation in RAW 264.7 cells induced by lipopolysaccharide (LPS), with an IC50 value of 36.6 μM. This compound is valuable for research applications focused on inflammation and related signaling pathways. -
iNOS Inhibitor
1-Heptadecanoyl-rac-glycerol is an iNOS inhibitor that exhibits anti-inflammatory activity. By suppressing the expression of inducible nitric oxide synthase (iNOS), it effectively reduces inflammation. This compound is suitable for research applications focused on inflammatory diseases and related pathologies. -
NO Synthase Inhibitor
S-MTC acetate (S-Methyl-L-thiocitrulline acetate) is a potent inhibitor of inducible nitric oxide synthase (iNOS), selectively inhibiting iNOS while preserving the activity of constitutive nitric oxide synthase (nNOS). This compound is valuable for studying the roles of nitric oxide in various physiological and pathological processes, particularly in inflammation and neuroprotection research. Its specificity makes it an important tool for investigating the differential effects of nitric oxide in cellular signaling pathways. -
NO Release Inhibitor
Schisanchinin D is an NO release inhibitor derived from the fruits of Schisandra chinensis. It effectively inhibits the release of nitric oxide (NO) in lipopolysaccharide (LPS)-activated primary murine BV2 microglia cells. This compound holds potential for research in neurodegenerative diseases, particularly Alzheimer's disease (AD), due to its impact on microglial activation and neuroinflammatory processes. -
Anti-inflammatory Agent
Anti-inflammatory agent 63 is an anti-inflammatory compound that specifically inhibits nitric oxide (NO) production in RAW264.7 cells induced by lipopolysaccharide (LPS), with an EC50 value of 5.33±0.57 μM. This reagent is valuable for research applications focused on inflammation mechanisms and the modulation of immune responses. Its potency makes it a useful tool for investigating potential therapeutic strategies against inflammatory diseases. -
NO Synthase Inhibitor
Rubranol is a selective inhibitor of nitric oxide (NO) synthase, significantly reducing NO production in response to lipopolysaccharide (LPS) stimulation in activated macrophages, achieving a notable 74% inhibition. This compound is useful for researchers studying inflammatory responses and the role of NO in various pathological conditions. Its specific action on NO synthase makes it a valuable tool for investigating the modulation of nitric oxide pathways in cellular processes. -
NO Production Inhibitor
3β,15α-Dihydroxy-7,11,23-trioxo-lanost-8-dien-26-oic acid is a triterpene compound with a primary mechanism as a nitric oxide (NO) production inhibitor. It effectively suppresses NO production in BV-2 microglial cells stimulated by lipopolysaccharide (LPS), demonstrating an IC50 value of 6.50 μM. This compound serves as a valuable tool for anti-inflammatory research, potentially contributing to the development of therapeutic strategies targeting inflammatory pathways. -
Anti-inflammatory Agent
1-O-Caffeoylglycerol is an anti-inflammatory compound derived from Sorghum bicolor. It demonstrates significant inhibition of LPS-induced nitric oxide production, with an IC50 value of 18.5 μM, and effectively reduces iNOS protein expression in a dose-dependent manner. This reagent is suitable for studies focused on inflammatory conditions and the exploration of potential therapeutic applications in related research fields. -
Negative Control
Sulpho NONOate is a negative control compound that does not release nitric oxide (NO) at physiological pH. This reagent is utilized in experiments involving other NO-donor agents to effectively establish baseline comparisons and validate the biological activity of those compounds. Its role as a control is essential for clarifying the specific effects of NO-donors in various biochemical and physiological studies. -
NO Synthase Antagonist
L-NMMA hydrochloride is a competitive antagonist of L-arginine, effectively inhibiting nitric oxide (NO) production by targeting nitric oxide synthase. This compound is widely used in research to study the role of nitric oxide in various physiological and pathological processes, such as vascular regulation and immune response modulation. Its application extends to exploring potential therapeutic interventions in conditions associated with dysregulated NO signaling. -
iNOS Inhibitor
N-Benzylacetamidine hydrobromide is a selective inhibitor of inducible nitric oxide synthase (iNOS), exhibiting an IC50 of 0.20 μM. This compound is valuable for research focused on the modulation of nitric oxide production in inflammatory processes. Its selective action makes it a suitable tool for studying iNOS-related pathophysiology and potential therapeutic applications in related diseases. -
NO Synthesis Inhibitor
(2R)-6-Methoxynaringenin is a selective inhibitor of nitric oxide (NO) synthesis. This flavonoid exhibits significant biological activity, with an IC50 value of 25.8 μM for NO production inhibition. Its ability to modulate NO levels makes it a valuable tool for research applications focused on vascular biology, inflammation, and associated signaling pathways. -
iNOS Inhibitor
Cindunistat is a selective inhibitor of inducible nitric oxide synthase (iNOS), demonstrating potent oral bioactivity. This compound is valuable for investigating the role of iNOS in various inflammatory and pathological conditions. Research applications include studies on cytokine modulation, neuroinflammation, and cardiovascular diseases, making it a crucial tool for exploring therapeutic interventions in nitric oxide-mediated pathways. -
iNOS Inhibitor
Demethylregelin is a triterpene that functions as an inhibitor of inducible nitric oxide synthase (iNOS). It effectively decreases iNOS protein expression and subsequent nitric oxide production in RAW264.7 macrophages upon lipopolysaccharide stimulation. This compound exhibits notable anti-inflammatory properties and is useful in research focusing on inflammatory signaling pathways and modulation of nitric oxide levels in cellular models. -
NO Synthase Inhibitor
NG-Amino-L-arginine hydrochloride is a potent inhibitor of nitric oxide synthase (NOS), specifically targeting the nNOS, iNOS, and eNOS isoforms. It effectively induces inactivation of these enzymes, with Ki values of 0.3 μM, 3 μM, and 2.5 μM, respectively. This reagent is valuable for research applications focused on the modulation of nitric oxide pathways and their roles in various physiological and pathological processes. -
NO Production Inhibitor
N-cis-Feruloyl tyramine is a natural phenolic compound that acts as an inhibitor of nitric oxide (NO) production. It demonstrates moderate inhibitory effects on lipopolysaccharide (LPS)-activated NO production in RAW 264.7 macrophage cells. This compound can be utilized in research to explore inflammatory responses and the modulation of NO signaling pathways. -
NO Synthase Inhibitor
Anti-inflammatory agent 1 is a nitric oxide synthase inhibitor that modulates inflammatory processes by reducing nitric oxide production. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research focused on conditions characterized by excessive inflammation. Its applications extend to studying various inflammatory pathways and assessing the therapeutic potential of nitric oxide modulation in diverse biological contexts. -
NTPDase
Apyrase is a nucleoside triphosphate diphosphohydrolase (NTPDase) that hydrolyzes extracellular adenosine triphosphate (ATP) and adenosine diphosphate (ADP). This enzymatic activity inhibits the release of Shiga toxin 2 (Stx2) from enterohemorrhagic Escherichia coli (EHEC), thereby providing protection to intestinal barrier function. Apyrase is a valuable tool for investigating mechanisms of infection and inflammation, particularly in studies related to hemorrhagic colitis. -
NTPDase Inhibitor
PSB-06126 is a selective inhibitor of nucleoside triphosphate diphosphohydrolase (NTPDase), demonstrating Ki values of 0.33 μM for rat NTPDase 1, 19.1 μM for NTPDase 2, and 2.22 μM for NTPDase 3. In human NTPDase 3, it exhibits an IC50 value of 7.76 μM and a Ki value of 4.39 μM. This compound is useful for studying the role of NTPDases in purinergic signaling and may aid in the exploration of therapeutic strategies targeting related pathological conditions. -
NTPDase2 Inhibitor
PSB-16131 is a potent non-competitive inhibitor of human NTPDase2, exhibiting an IC50 value of 539 nM. This compound is valuable for investigating the roles of NTPDase2 in various biological contexts, including inflammation, neurodegenerative diseases, and cancer research. Its inhibitory effects can facilitate the exploration of biochemical pathways associated with these conditions. -
NTPDases Inhibitor
PSB069 is a nonselective inhibitor of NTPDases 1, 2, and 3, featuring a p-chlorophenylamino moiety. With an inhibition constant (Ki) ranging from 16 to 18 μM, this compound exhibits potent activity against these enzymes. PSB069 is valuable for research applications aimed at elucidating the role of NTPDases in various cellular processes and understanding their implications in disease mechanisms. -
NTPDase Inhibitor
NTPDase-IN-2 is a selective inhibitor of NTPDase with IC50 values of 0.04 µM for human NTPDase-2 and 2.27 µM for human NTPDase-8. This compound exhibits non-competitive inhibition of NTPDase-1 and NTPDase-2, with a Km of 74 µM for NTPDase-2. NTPDase-IN-2 is suitable for investigating its effects in cancer research, immunologic disorders, and bacterial infections. -
NTPDase Inhibitor
h-NTPDase-IN-5 is a pan-inhibitor of NTPDase enzymes, demonstrating IC50 values of 1.10 μM for h-NTPDase1, 44.73 μM for h-NTPDase2, 26.14 μM for h-NTPDase3, and 0.32 μM for h-NTPDase8. This compound effectively modulates ATP metabolism by targeting ecto-nucleotide triphosphate diphosphohydrolases, making it a valuable tool for investigating purinergic signaling pathways. Its inhibitory profile supports research applications in cell signaling, neurobiology, and the study of various pathophysiological conditions related to nucleotide signaling. -
ENTPD1/CD39 Antibody
Mebarase alfa is a human monoclonal antibody directed against ENTPD1/CD39. This reagent is particularly useful for investigating sepsis-associated renal injury, facilitating research into mechanisms of renal dysfunction and potential therapeutic interventions. Its specificity for ENTPD1/CD39 enables detailed exploration of immune regulation and purinergic signaling in pathophysiological contexts. -
NTPDase Inhibitor
NTPDase-IN-3 is a potent inhibitor of NTPDase enzymes, demonstrating IC50 values of 0.05 μM for NTPDase8, 0.38 μM for NTPDase3, 0.21 μM for NTPDase1, and 1.07 μM for NTPDase2. This compound plays a significant role in the regulation of nucleotide signaling pathways and is a valuable tool for research focused on cancer and thrombosis. Its specificity and effectiveness in modulating NTPDase activity make it essential for studies investigating these critical biological processes. -
NTPDase Inhibitor
h-NTPDase-IN-3 is a potent pan-inhibitor of NTPDase enzymes, demonstrating varying inhibitory activity with IC50 values of 34.13 μM for h-NTPDase1, 0.33 μM for h-NTPDase2, 23.21 μM for h-NTPDase3, and 2.48 μM for h-NTPDase8. This compound is valuable for research focused on purinergic signaling, offering insights into the regulation of extracellular nucleotide levels. Its ability to inhibit multiple NTPDase isoforms makes it suitable for studies exploring their roles in various physiological and pathological processes. -
NTPDase Inhibitor
NTPDase-IN-1 is a selective inhibitor targeting NTPDase enzymes, exhibiting IC50 values of 0.05, 0.23, and 0.54 µM for human NTPDase-1, -2, and -8 respectively. This compound acts as a non-competitive inhibitor for NTPDase-1 and -2, displaying a Km of 21 µM for NTPDase-1. NTPDase-IN-1 is applicable in research focused on cancer, immunological disorders, and bacterial infections. -
h-NTPDases 8 Inhibitor
h-NTPDase8-IN-1 is a selective inhibitor of human NTPDase8, exhibiting an IC50 value of 0.28 μM. This compound, classified as a sulfamoyl-benzamide, plays a crucial role in the modulation of physiological and pathological processes, including thrombosis, diabetes, inflammation, and cancer. Its potent inhibition of h-NTPDase8 makes it a valuable tool for research applications targeting these diverse biological functions. -
NTPDase Inhibitor
h-NTPDase-IN-4 is a potent pan-inhibitor of NTPDase, demonstrating IC50 values of 3.58 μM against h-NTPDase1, 10.21 μM against h-NTPDase2, 0.13 μM against h-NTPDase3, and 13.57 μM against h-NTPDase8. This compound selectively modulates nucleotide metabolism and purinergic signaling pathways, making it a valuable tool for research in cellular communication, inflammation, and cancer biology. Its broad activity across multiple NTPDase isoforms positions it as a significant reagent for studies investigating the role of purinergic receptors in various physiological and pathological processes. -
TcNTPDase1 Inhibitor
TcNTPDase1-IN-1 is a potent inhibitor of nucleoside triphosphate diphosphohydrolase 1 (TcNTPDase1) derived from Trypanosoma cruzi. This compound demonstrates key biological activities relevant to antibacterial, antitoxic, and antitumor research applications. By selectively targeting TcNTPDase1, TcNTPDase1-IN-1 provides valuable insights into its role in disease mechanisms and may aid in the development of therapeutic strategies against infections and cancer. -
Anti-osteoclastogenic Agent
NFATc1-IN-1 is a potent inhibitor of RANKL-induced osteoclast formation, exhibiting an IC50 of 1.57 μM. This compound exerts its anti-osteoclastogenic effects by disrupting the RANKL-mediated nuclear translocation of NFATc1. NFATc1-IN-1 is a valuable tool for research into osteoclastic diseases, providing insights into the regulation of osteoclastogenesis. -
Non-steroidal Anti-inflammatory Agent
Pirprofen is an orally active non-steroidal anti-inflammatory agent that functions as a reversible inhibitor of prostaglandin synthetase. Its key biological activities include anti-inflammatory, analgesic, and antipyretic effects, while also inhibiting leucocyte chemotaxis and the secondary phase of platelet aggregation triggered by collagen and arachidonic acid. This compound is of particular interest for research focused on inflammatory diseases and associated mechanisms. Note that pirprofen may also induce hepatotoxicity, warranting careful consideration in experimental applications. -
mPGES1 Inhibitor
CAY10526 is a selective inhibitor of microsomal prostaglandin E2 synthase-1 (mPGES1), exerting its effects by specifically modulating mPGES1 expression without influencing cyclooxygenase-2 (COX-2). This compound effectively reduces PGE2 production, leading to significant suppression of tumor growth and enhanced apoptosis in melanoma xenografts. CAY10526 downregulates anti-apoptotic proteins BCL-2 and BCL-XL while elevating levels of pro-apoptotic proteins BAX and BAK, along with cleaved caspase-3, promoting cell death. It demonstrates potent cytotoxicity with an IC50 of less than 5 μM in melanoma cell lines expressing mPGES1, making it valuable for cancer research and therapeutic studies. -
mPGES-1 Inhibitor
Vipoglanstat is a potent and selective non-peptide inhibitor of human microsomal prostaglandin E synthase-1 (mPGES-1). As a carboxamide derivative, it demonstrates significant anti-inflammatory activity, making it a valuable tool in research focusing on inflammation-related diseases. Its oral bioavailability facilitates in vivo studies aimed at understanding the role of mPGES-1 in various pathological conditions. -
PGE synthase Inhibitor
Zomepirac sodium salt is a potent inhibitor of prostaglandin E synthase, exhibiting significant anti-inflammatory properties. As a non-steroidal anti-inflammatory drug (NSAID), Zomepirac sodium salt is primarily utilized in research to study prostaglandin biosynthesis and related inflammatory processes. It is noteworthy that this compound has been associated with immune-mediated liver injury, highlighting its importance in pharmacological safety assessments. -
mPGES-1 Inhibitor
mPGES1-IN-7 is a benzimidazole-derived inhibitor targeting microsomal prostaglandin E synthase-1 (mPGES-1). It significantly reduces prostaglandin E2 (PGE2) production and exhibits inhibitory effects on other prostaglandins. mPGES1-IN-7 has demonstrated effectiveness in mitigating acute inflammation, as evidenced in a Carrageenan-induced air sac model in mice, making it a valuable tool for research in inflammation and related biological pathways.
